step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Once-Weekly in Adults with Overweight or Obesity Semaglutide in Patients with Obesity-Related

These typically improve with dietary adjustments

Other reported symptoms Sources: Phase 3 TRIUMPH-4 trial and Phase 2 NEJM trial Dysesthesia, or a change in skin sensation, was a new finding in the Phase 3 trial

QS-GLP1-S (Semaglutide) can help reduce the risk of cardiovascular disease by promoting weight loss, improving blood sugar control, and reducing blood pressure and cholesterol levels

Participants who took this medication, along with lifestyle interventions, lost significantly more weight than those who solely made lifestyle changes

Individuals with certain variants may benefit from dual-agonist therapy like GLP-Squared Injection (combining semaglutide and tirzepatide) rather than monotherapy alone

Flu-Like Symptoms Who gets Flu-Like Symptoms